Effect of Defrasirox on ferritin and iron overload in Thalassemia Disease
Phase 4
- Conditions
- major thalassemia.Thalassemia, unspecified
- Registration Number
- IRCT2015071823245N1
- Lead Sponsor
- Research Center of Golestan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 58
Inclusion Criteria
Patients with major thalassemia with blood transfusions and treatment with Deferiprone with Deferoxamine; Ferritin levels below 5000ng/ml.
Exclusion criteria:The patient dissatisfaction; drug intolerance.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum ferritin. Timepoint: Baseline, 3 month6month,9month,12month. Method of measurement: sampling and serum ferritin level(ng/ml).;Changes of MRI T2* normally, involves mild, moderate, severe. Timepoint: baseline, after one year. Method of measurement: MRI and The speed Back in phase T2* With millisecondand and classificate into four groups: normal, mild, moderate, severe.
- Secondary Outcome Measures
Name Time Method